Agalsidase alfa

Therapeutic indications

Agalsidase alfa is indicated for:

Fabry Disease

Population group: both men and women, only adults (18 - 65 years old)

Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.2 mg/kg every other week

Fabry Disease

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.2 mg/kg every other week

Contraindications

Agalsidase alfa is contraindicated in the following cases:

Chloroquine

Chloroquine

Amiodarone

Amiodarone

Gentamicin

Gentamicin

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines